Objective To investigate the therapeutic efficacy of bortezomib+dexamethasone+lenalidomide(VRD-lite) regimen on multiple myeloma and its effect on the expression of serum miR-223-3p and miR-140-5p. Methods Ninety patients with multiple myeloma admitted to the Department of Hematology of the First Hospital Affiliated to Hebei North College from June 2020 to June 2023 were selected as the study subjects, and were divided into the control group and the study group by the envelope method, each with 45 cases. The control group was treated with bortezomib combined with dexamethasone, and the study group was treated with lenalidomide based on the control group therapy. We compared the effect of the 2 groups after 3 months of treatment, serum miR-223-3p, miR-140-5p expression, myeloma examination, inflammatory response, renal function indexes, and patients' survival quality.Results The total effective rate of treatment in the study group was 86.67%, which was higher than 68.89% in the control group( χ2/P=4.114/0.043); after the treatment, the expression levels of serum miR-223-3p and miR-140-5p in both groups were elevated, and the study group was higher than the control group. were elevated, and the study group was higher than the control group( t/P=4.590/<0.001, 4.257/<0.001). Serum M protein, β2 microglobulin, and proportion of myeloma cells levels were decreased in the 2 groups after treatment and were lower in the study group than in the control group( t/P=11.783/<0.001, 37.964/<0.001, 11.493/<0.001). IL-6, IL-17, TGF-β, SCr, BUN, 24-h urine protein levels and PS scores were lower in both groups after treatment compared with before treatment, and lower in the study group( t/P=21.920/<0.001, 69.118/<0.001, 5.066/<0.001,16.822/<0.001,8.183/<0.001,3.472/0.001,4.525/<0.001), KPS and QOL scores were elevated and higher in the study group than in the control group( t/P=14.156/<0.001, 15.250/<0.001). Conclusion VRD-lite regimen has significant efficacy in the treatment of multiple myeloma, which can significantly improve the renal function, inflammatory response status and quality of life, and positively affect the expression of serum miR-223-3p and miR-140-5p.

Objective To investigate the relationship between serum proprotein convertase subtilisin/kexin type 9(PCSK9), Syndecan-1, soluble suppression of tumorigenicity-2(sST2) and the condition of patients with traumatic shock and infection, and their impact on prognosis. Methods Totally 95 patients with traumatic shock and infection admitted to the Emergency Department of Central Theater General Hospital were included and labeled as infection group. The patients' condition was evaluated using the APACHE-Ⅱ scale and grouped into mild, moderate, and severe subgroup( n=54) and( n=41). Complying with the 28-day prognosis after admission, the patients were included into the survival group( n=64) and the death group( n=31). Meantime, another 95 patients with simple traumatic shock were labeled as control group. ELISA method was used to detect serum PCSK9, Syndecan-1, and sST2. Multiple logistic regression model was used to analyze the factors that affected prognosis. ROC curve was used to analyze the prognostic value of serum PCSK9, Syndecan-1, and sST2. Results For the control group, the infection group showed clearly upregulated serum PCSK9, Syndecan-1, and sST2( t/P=23.438/<0.001, 17.338/<0.001, 16.641/<0.001). For the mild and moderate groups, the severe group had clearly higher serum PCSK9, Syndecan-1, and sST2( t/P=7.211/<0.001, 7.756/<0.001, 6.819/<0.001). For the survival group, the death group had clearly higher lymphocyte counts, serum PCSK9, Syndecan-1, and sST2( t/P=6.079/<0.001, 7.012/<0.001, 6.682/<0.001, 6.523/<0.001). The high expression of PCSK9, Syndecan-1, and sST2 was a risk factor for mortality[OR(95%)CI=2.059(1.220-3.475), 2.234(1.212-4.118), 1.957(1.338-2.862)]. The serum levels of PCSK9, Syndecan-1 and sST2 and the AUC predicted by the prognosis of patients with traumatic shock and infection were 0.823, 0.817, 0.821 and 0.939, respectively, and the AUC predicted by the three combined was better than that predicted by the three patients alone(Z/P=2.803/0.005, 2.450/0.014, 2.444/0.015). Conclusion The PCSK9, Syndecan-1, and sST2 are upregulated in serum of patients with traumatic shock and infection. The three factors are closely related to the severity of condition and are important factors affecting the prognosis. The combined detection can effectively improve the evaluation value for prognosis.

Objective To investigate the changes in serum levels of high mobility protein B1(HMGB1) and apolipoprotein B/apolipoprotein A1(ApoB/ApoA1) in patients with pregnancy induced hypertension, and to analyze their diagnostic value for early renal damage in patients.Methods One hundred and eighteen cases of gestational hypertension admitted to the Department of Obstetrics and Gynecology of the First Hospital of Northwestern University from July 2020 to July 2023 were selected as the gestational hypertension group, and the patients were categorized into the subgroups of gestational hypertension(43 cases), mild preeclampsia(38 cases), and severe preeclampsia(37 cases) according to the degree of hypertension, while 118 cases of women with normal pregnancies during the same period were selected as the normal pregnancy group. The hyperemesis gravidarum group was divided into a renal impairment subgroup(32 cases) and a non-renal impairment subgroup(86 cases) based on the occurrence of renal impairment. Serum HMGB1 levels were measured by enzyme-linked immunosorbent assay(ELISA), and ApoB and ApoA1 levels were measured by fully automated biochemical analyzer. Comparison of serum HMGB1 and ApoB/ApoA1 levels in patients with different severity of disease. Comparison of patient data and serum HMGB1 and ApoB/ApoA1 levels in the renal impairment subgroup and the non-renal impairment subgroup. Multifactorial logistic regression analysis of the factors influencing the occurrence of early kidney damage in patients with hyperemesis gravidarum. Diagnostic value of serum HMGB1 and ApoB/ApoA1 levels in early renal damage in patients with hyperemesis gravidarum analyzed by using subject operating characteristic(ROC) curves. Results Serum HMGB1 and ApoB/ApoA1 levels were higher in patients in the hyperemesis gravidarum group than in the normal pregnancy group( t/P=29.806/<0.001, 22.378/<0.001). Serum HMGB1 and ApoB/ApoA1 levels were higher in patients with hyperemesis gravidarum the more severe the condition( t/P=51.726/<0.001, 143.231/<0.001). Serum HMGB1 and ApoB/ApoA1 levels were higher in patients in the renal damage subgroup than in the non-renal damage subgroup( t/P=8.346/<0.001, 8.582/<0.001). High serum HMGB1 and ApoB/ApoA1 levels are influential factors in the development of early renal damage in patients with hyperemesis gravidarum[OR(95%CI)=6.887(3.309-14.335), 8.887(3.766-20.970)]. The AUCs of serum HMGB1, ApoB/ApoA and the combination of the two for predicting early kidney damage in patients with hyperemesis gravidarum were 0.840, 0.836, and 0.938, respectively, and the combination of the two was superior to the efficacy of their respective individual predictions(Z=3.321, 3.481, P=0.001, <0.001).Conclusion Serum levels of HMGB1 and ApoB/ApoA1 are elevated in patients with preeclampsia, and have high diagnostic value in diagnosing early renal damage.

Objective To study the expression of NOP2/Sun RNA methyltransferase 6(NSUN6) and Sulfatase 1(SULF1) in cervical cancer tissues and their relationship with clinicopathological features and prognosis.Methods The expression differences of NSUN6 and SULF1 in cervical cancer tissues and normal cervical tissues in the human genome atlas database were analyzed by R language. The clinical data of 92 patients with cervical cancer admitted to the Department of gynecology and obstetrics of Guizhou Medical University Affiliated Hospital from June 2019 to June 2021 were collected. The expression of NSUN6 and SULF1 in cancer tissues was detected by real-time fluorescence quantitative PCR and immunohistochemistry; K-M curve was used to compare the prognostic differences of different NSUN6 and SULF1 protein expressions in patients with cervical cancer; Cox regression model was used to screen the prognostic factors of cervical cancer.Results The results of TCGA database and qPCR showed that the expression of NSUN6 mRNA and SULF1 mRNA in cervical cancer tissues was higher than that in normal tissues( t/P=22.281/<0.001,53.721/<0.001,37.619/<0.001,36.442/<0.001);The positive rates of NSUN6 and SULF1 proteins in cervical cancer tissues were higher than those in adjacent tissues( t/P=85.546/<0.001,86.891/<0.001).The positive rates of NSUN6 and SULF1 in cervical cancer tissues with FIGO stage ⅠB2-ⅡB and lymph node metastasis were higher than those of ⅠA-ⅠB1 and no lymph node metastasis( t/P=7.934/0.005,5.327/0.021,13.512/<0.001,4.564 .="" there="" was="" no="" significant="" difference="" in="" 3-year="" overall="" survival="" rate="" between="" nsun6="" positive="" and="" sulf1="" p="">0.05); The 3-year progression-free survival rate of NSUN6 positive and SULF1 positive was lower than that of NSUN6 negative and SULF1 negative( χ2/P=8.120/0.004,36.442/<0.001). NSUN6 positive, SULF1 positive, FIGO stage ⅠB2-ⅡB and lymph node metastasis were risk factors affecting the prognosis of cervical cancer[HR(95%CI)=1.374(1.082-1.746),1.278(1.054-1.548),1.402(1.115-1.764),1.339(1.094-1.639)].Conclusion The expressions of NSUN6 and SULF1 mRNA and protein in cervical cancer tissues are increased, both of which are related to poor clinicopathological features and are markers for evaluating the prognosis of cervical cancer.

Objective To investigate the relationship between the expression of microRNA-22-3p(miR-22-3p), Erb-B2 receptor tyrosine kinase 3(ERBB3), epithelial-mesenchymal transition(EMT), and prognosis in cervical cancer(CC) tissues. Methods A total of 154 CC patients who underwent total or radical hysterectomy at the Department of Obstetrics and Gynecology, Eastern Theater General Hospital, from January 2018 to June 2021 were selected. The expression levels of miR-22-3p, ERBB3, and EMT markers(N-cadherin, E-cadherin, SNAI1, Vimentin) in CC tissues and matched adjacent normal tissues were detected using real-time quantitative PCR. The binding site of miR-22-3p and ERBB3 was predicted through an online database. Pearson correlation analysis was used to assess the correlation between the expression of miR-22-3p, ERBB3, and EMT markers in CC tissues. Based on the mean expression levels of miR-22-3p and ERBB3 in CC tissues, patients were divided into high-expression and low-expression groups. Kaplan-Meier survival curves were plotted for progression-free survival based on different miR-22-3p and ERBB3 mRNA expressions. Multivariate Cox regression analysis was performed to evaluate the relationship between miR-22-3p and ERBB3 mRNA expression and prognosis in CC patients. Results Compared with adjacent normal tissues, CC tissues showed lower expression of miR-22-3p and E-cad mRNA, but higher expression of ERBB3 mRNA, N-cad mRNA, SNAI1 mRNA, and VIM mRNA( t/P=-29.759/<0.001,-30.944/<0.001,36.216/<0.001,35.503/<0.001,22.026/<0.001,36.849/<0.001).A binding site between miR-22-3p and ERBB3 was found at the 3' untranslated region(positions 36-43). In CC tissues, miR-22-3p was negatively correlated with ERBB3 mRNA, N-cad mRNA, SNAI1 mRNA, and VIM mRNA, but positively correlated with E-cad mRNA( r/P=-0.795/<0.001,-0.744/<0.001,-0.681/<0.001,-0.761/<0.001,0.756/<0.001); ERBB3 mRNA was positively correlated with N-cad mRNA, SNAI1 mRNA, and VIM mRNA, and negatively correlated with E-cad mRNA( r/P=0.741/<0.001,0.680/<0.001,0.730/<0.001,-0.768/<0.001).Lower expression of miR-22-3p and higher expression of ERBB3 mRNA were observed in poorly differentiated tumors, FIGO stage Ⅲ, and cases with lymph node metastasis compared to moderately/highly differentiated tumors, FIGO stage Ⅰ-Ⅱ, and those without lymph node metastasis( t/P=2.907/0.004,3.092/0.002,3.485/0.001,2.891/0.004,3.113/0.002,3.505/0.001).The 3-year progression-free survival rate for the 154 CC patients was 65.58%(101/154). Patients with high miR-22-3p expression had a higher 3-year progression-free survival rate compared to those with low expression, while patients with high ERBB3 mRNA expression had a lower 3-year progression-free survival rate compared to those with low expression( χ2/P=17.390/<0.001,16.122/<0.001).Poor differentiation, FIGO stage Ⅲ, lymph node metastasis, and ERBB3 mRNA ≥2.39 were independent risk factors for tumor progression in CC patients, while miR-22-3p ≥1.32 was an independent protective factor[OR(95%CI)=3.500(1.820-6.731), 2.309(1.111-4.798), 4.403(2.224-8.716), 4.237(1.987-9.037), 0.318(0.157-0.644)]. Conclusion Low expression of miR-22-3p and high expression of ERBB3 mRNA in CC tissues are associated with poor pathological features, EMT, and prognosis, and they may serve as novel biomarkers for assessing EMT and prognosis in CC patients.